Below is the current list of studies covered by the CIRB. It includes both Available to Open and Completed studies. Study documents approved after July 1, 2013 for all covered studies are available on the CTSU website.
To request documents approved before July 1, 2013, please contact the CIRB Helpdesk.
|Study Number||Lead Group||Study Title||CIRB||Study Status|
|9742||ETCTN||Multicenter Phase II Study of Nivolumab in Previously Treated Patients with Recurrent and Metastatic Nasopharyngeal Carcinoma||Adult CIRB - Early Phase Emphasis||Available to Open|
|9706||ETCTN||Randomized phase II study to assess the role of Nivolumab as single agent to eliminate minimal residual disease and maintain remission in acute myelogenous leukemia (AML) patients after chemotherapy (REMAIN Trial)||Adult CIRB - Early Phase Emphasis||Available to Open|
|9681||ETCTN||A Phase 1 Study of Cabozantinib plus Nivolumab (CaboNivo) Alone or in Combination with Ipilimumab (CaboNivoIpi) in Patients with Advanced/Metastatic Urothelial Carcinoma and other Genitourinary Tumors.||Adult CIRB - Early Phase Emphasis||Available to Open|
|9676||ETCTN||A Phase 1 Trial of MK-3475 Plus Ziv-Aflibercept in Patients with Advanced Solid Tumors||Adult CIRB - Early Phase Emphasis||Available to Open|
|9673||ETCTN||A Multi-Institutional Phase II Study of Nivolumab in Refractory Metastatic Squamous Cell Carcinoma of the Anal Canal||Adult CIRB - Early Phase Emphasis||Available to Open|
|9672||ETCTN||A Phase 2 Study of Nivolumab in Advanced Leiomyosarcoma of the Uterus||Adult CIRB - Early Phase Emphasis||Available to Open|
|9671||ETCTN||Exceptional Responders Pilot study: Molecular profiling of tumors from cancer patients who are Exceptional responders||Adult CIRB - Early Phase Emphasis||Available to Open|
|9653||ETCTN||Phase II Trial of Gemcitabine-Eribulin (GE) in Cisplatin Ineligible Patients with Advanced or Unresectable Unrothelial Carcinoma of the Bladder||Adult CIRB - Early Phase Emphasis||Completed|
|9608||ETCTN||A Phase I Trial of ABT-263 (Navitoclax); a Bcl-2 inhibitor; and Sorafenib (Nexavar) in Patients with Relapsed or Refractory Solid Organ Tumors||Adult CIRB - Early Phase Emphasis||Available to Open|
|9571||ETCTN||A phase IB study of the combination of AZD6244 hydrogen sulfate (selumetinib) and cyclosporin A (CsA) in patients with advanced solid tumors with an expansion cohort in metastatic colorectal cancer||Adult CIRB - Early Phase Emphasis||Completed|